35794-84-4

Basic information

• Product Name: 2-ACETYL-4-CYANOPHENOL
• Synonyms: 2-ACETYL-4-CYANOPHENOL;RARECHEM BW GA 0369;Benzonitrile, 3-acetyl-4-hydroxy- (6CI,7CI,9CI);Benzonitrile, 3-acetyl-4-hydroxy-;4'-Cyano-2'-hydroxyacetophenone
• CAS NO: 35794-84-4
• Molecular Formula: C₉H₇NO₂
• Molecular Weight: 161.16
• Product Categories: ACETYLGROUP
• Mol File: 35794-84-4.mol
• Article Data: 9

Chemical Properties

• Melting Point: 103 °C
• Boiling Point: 313.475 °C at 760 mmHg
• Flash Point: 143.385 °C
• Appearance: /
• Density: 1.268 g/cm³
• Vapor Pressure: 0.000269mmHg at 25°C
• Refractive Index: 1.578
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 8.04±0.18(Predicted)
• CAS DataBase Reference: 2-ACETYL-4-CYANOPHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-ACETYL-4-CYANOPHENOL(35794-84-4)
• EPA Substance Registry System: 2-ACETYL-4-CYANOPHENOL(35794-84-4)

Safety Data

• Hazardous Substances Data: 35794-84-4(Hazardous Substances Data)

Usage

Preparation

Obtained by heating a mixture of 4-cyanophenyl acetate and aluminium chloride at 180–185° for 2 h (58%).

InChI:InChI=1/C9H7NO2/c1-6(11)8-4-7(5-10)2-3-9(8)12/h2-4,12H,1H3

Upstream product

• 1450-75-5 5-Bromo-2-hydroxyacetophenone 
• 767-00-0 4-cyanophenol 
• 13031-41-9 4-cyanophenyl acetate 
• 123-75-1 pyrrolidine 
• 692-86-4 ethyl 10-undecenenoate 
• 98-86-2 acetophenone 

Downstream Products

• 1323443-76-0 N-(6-cyano-3,4-dihydro-3-hydroxyspiro[2H-1-benzopyran-2,1'-cyclohexane]-4-yl)-L-phenylalanine ethyl ester 
• 1323443-77-1 N-(6-cyano-3,4-dihydro-3-hydroxyspiro[2H-1-benzopyran-2,1'-cyclohexane]-4-yl)-L-tyrosine ethyl ester 
• 1323443-70-4 N-(6-cyano-3,4-dihydro-2,2-dimethyl-3-hydroxy-2H-1-benzopyran-4-yl)-L-phenylalanine ethyl ester 
• 1323443-71-5 N-(6-cyano-3,4-dihydro-2,2-dimethyl-3-hydroxy-2H-1-benzopyran-4-yl)-L-tyrosine ethyl ester 
• 1323443-73-7 N-(6-cyano-3,4-dihydro-3-hydroxyspiro[2H-1-benzopyran-2,1'-cyclopentane]-4-yl)-L-phenylalanine ethyl ester 
• 1323443-74-8 N-(6-cyano-3,4-dihydro-3-hydroxyspiro[2H-1-benzopyran-2,1'-cyclopentane]-4-yl)-L-tyrosine ethyl ester 
• 1450930-02-5 4-oxo-8-phenyl-2-(pyridin-4-yl)-4H-chromene-6-carboxamide 
• 1450930-01-4 2-morpholino-4-oxo-8-phenyl-4H-chromene-6-carboxamide 
• 1450930-00-3 4-oxo-8-phenyl-2-(pyridin-4-yl)-4H-chromene-6-carbonitrile 
• 1450929-99-3 2-morpholino-4-oxo-8-phenyl-4H-chromene-6-carbonitrile 
• 1450930-14-9 3-bromo-4-hydroxy-5-(3-morpholino-3-oxopropanoyl)benzonitrile 
• 1450930-13-8 2-methyl-1-(5-(4-oxo-8-phenyl-2-(pyridin-4-yl)-4H-chromen-6-yl)-2H-tetrazol-2-yl)propyl pivalate 
• 1450930-12-7 2-methyl-1-(5-(2-morpholino-4-oxo-8-phenyl-4H-chromen-6-yl)-2H-tetrazol-2-yl)propyl pivalate 
• 1450930-11-6 8-phenyl-2-(pyridin-4-yl)-6-(2H-tetrazol-5-yl)-4H-chromen-4-one 

Relevant articles and documents

A facile strategy for accessing 3-alkynylchromones through gold-catalyzed alkynylation/cyclization of o-hydroxyarylenaminones

A strategy based on tandem alkynylation of o-hydroxyarylenaminones followed by intramolecular cyclization has been developed to generate a diverse array of 3-alkynyl chromones. The functionality embedded in these key intermediates enables their facile elaboration into more diverse structures by a variety of functionalizations and ring-forming processes.

Potent Inhibitors of Phosphatidylinositol3 (PI3) Kinase that have Antiproliferative Activity Only When Delivered as Prodrug Forms

Prodrugs for PI3K: A series of substituted analogues of the phosphatidylinositol3 kinase (PI3K) inhibitor LY294002 were prepared and found to potently inhibit the isolated enzyme but not MCF7 cell proliferation. Two tetrazolyl-substituted analogues were further derivatized as prodrugs resulting in restoration of cell-based activity. These data provide a conceptual model for development of tumor-targeting prodrug forms of cell-impermeable PI3K inhibitors. Copyright

N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof

N-sulfamoyl-N′-benzopyranpiperidine compounds of formula I and their physiologically acceptable acid addition salts, pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment and/or inhibition of glaucoma, epilepsy, bipolar disorders, migraine, neuropathic pain, obesity, type II diabetes, metabolic syndrome, alcohol dependence, and/or cancer, and related concomitant and/or secondary diseases or conditions.